35.52

0.20% 0.04

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $35.52, with a volume of 57,140. It is up +0.20% in the last 24 hours and down -9.45% over the past month. Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Previous Close:

$35.48

Open:

$35.44

24h Volume:

57,140

Relative Volume:

0.14

Market Cap:

$2.74B

Revenue:

$13.17M

Net Income/Loss:

$-199.06M

P/E Ratio:

-12.96

EPS:

-2.74

Net Cash Flow:

$-156.53M

1W Performance:

-4.64%

1M Performance:

-9.45%

6M Performance:

-12.95%

1Y Performance:

-21.14%

1-Day Range:

$35.07

$36.22

1-Week Range:

$33.81

$38.08

52-Week Range:

$33.27

$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

327

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	35.49	2.74B	13.17M	-199.06M	-156.53M	-2.74
VRTX Vertex Pharmaceuticals Inc	500.75	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	679.31	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.80	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.16	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

Mar 12, 2025

Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks

Mar 12, 2025

Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times

Mar 12, 2025

Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - StockTitan

Mar 12, 2025

Mar 07, 2025

Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 07, 2025

Mar 06, 2025

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Mar 06, 2025

Mar 05, 2025

Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com

Mar 05, 2025

Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 04, 2025

New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online

Mar 04, 2025

Mar 03, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World

Mar 02, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World

Mar 02, 2025

Feb 28, 2025

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN

Feb 28, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat

Feb 28, 2025

HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat

Feb 28, 2025

Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks

Feb 28, 2025

Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks

Feb 28, 2025

Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - Marketscreener.com

Feb 28, 2025

Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com

Feb 28, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks

Feb 28, 2025